The One Tesamorelin Number the Trials Actually Back, and the Two Things That Keep It Safe

The overview

Anyone who types “tesamorelin dose” into a search bar usually lands, within a few clicks, on a forum thread full of confident numbers. Milligrams, frequencies, “cycles” that sound almost clinical. This page is not going to add one more of those lists. Instead, it is going to do something more useful: show exactly where the real evidence stops, so the difference between a number that came out of a clinical trial and a number that came out of a comment thread is easy to spot.

Tesamorelin is FDA-approved as Egrifta for one specific problem. The body-composition and anti-aging uses it gets marketed for online are off-label, and no trial has established a dose for those uses. That distinction runs through everything below.

The worry

Here’s the worry, stated plainly: a dosing number by itself feels like enough information to act on. It isn’t. A milligram figure, taken out of the context it was tested in, can quietly drop the parts that made it safe in the first place. That’s exactly what happens with tesamorelin. There is one dose with real trial data behind it, and most of what circulates online has stripped away the two conditions that dose came with.

The answer

So, the number. The FDA-approved dose of tesamorelin on the Egrifta label is 2 mg, injected subcutaneously, once daily [R5]. That is the dose used in the trials that got the drug approved, and it remains the only dose with serious human evidence behind it.

It’s worth seeing where that figure actually comes from. A 2007 trial published in the New England Journal of Medicine randomized 412 HIV patients with abdominal fat accumulation to 2 mg of tesamorelin daily or placebo for 26 weeks. The tesamorelin group lost 15.2% of their visceral fat, while the placebo group actually gained 5.0% [R1]. A 2010 pooled analysis of two Phase 3 trials, 806 patients in total, confirmed the results held up to 52 weeks at that same daily dose [R2]. Then in 2019, a Lancet HIV trial used the identical 2 mg daily dose and found tesamorelin reduced liver fat in HIV patients [R3]. Across every trial that matters, the dose does not move. It is 2 mg, daily, full stop.

If someone hands over a different number, a natural next question is: where did that come from? If the answer isn’t “a trial,” it’s worth treating that number the same way you’d treat a stranger’s home remedy.

Think of a dose as a three-legged stool

Here’s a useful way to hold all of this: a dose is not really one number. It’s three things that have to stand together, and if any one leg is missing, the whole thing tips over.

Leg one is the milligrams. That’s the 2 mg daily figure everyone quotes.

Leg two is who was tested. Every trial behind that 2 mg number was conducted in people with HIV-associated lipodystrophy, the only population the FDA actually reviewed [R5]. The label states plainly that tesamorelin is not indicated for general weight loss. Anyone taking it off-label for fat loss or anti-aging purposes is borrowing a number that was validated in a different group, with a different underlying condition. It might transfer reasonably well. It might not. No trial has answered that question either way.

Leg three is the monitoring. The Egrifta label doesn’t stop at “2 mg daily.” It specifies monitoring patients for changes in glucose metabolism, including the possible development of impaired glucose tolerance or diabetes [R5]. That monitoring is part of the dose, not an optional add-on. The label also notes that the drug’s long-term cardiovascular safety has not been established [R5], which is one more reason the studied dose was never meant to be taken and forgotten.

Most forum protocols hand over leg one and quietly leave out legs two and three. That’s the easy third of the instruction, with the safety two-thirds deleted.

What responsible dosing actually looks like

Translating all this into something practical: responsible tesamorelin dosing isn’t a milligram figure at all. It’s a process.

It means someone qualified looks at an individual’s history, other medications, and diabetes risk before anything starts, and makes a real judgment about whether tesamorelin makes sense for that person. It means glucose is actually being watched, because the studied dose came bundled with that watching. It means the dose gets adjusted to the person in front of the clinician, rather than copied from a stranger online who shares none of that context. And it means there is someone to call if something feels off, rather than a browser tab that’s already closed.

The trials can say what dose worked for the people who were in them. They cannot say what’s safe for someone who wasn’t in the study, and that gap doesn’t get filled by a more detailed PDF. It gets filled by a clinician.

This is why the access route matters even for what looks like a simple dosing question. The supervised path runs through a licensed telehealth provider, where a clinician evaluates the patient and a licensed pharmacy fills the prescription, rather than a vial arriving with a disclaimer attached. FormBlends operates that way for tesamorelin: physician evaluation, a prescription written when it’s appropriate, and dispensing through a licensed pharmacy. It’s mentioned here as an example of what supervised access actually involves, not as a ranked recommendation. The structural point stands regardless of provider: the screening and glucose monitoring that the trials can’t hand you only exist when a clinician is genuinely part of the process.

The path: tracking as part of doing this safely

For anyone using tesamorelin under supervision, one habit pays off more than most people expect: writing things down. The effects build gradually over weeks, and the main thing being monitored, glucose, is precisely the kind of detail that gets fuzzy between appointments if it isn’t recorded.

A notebook works fine. A dedicated tool works too. The FormBlends tracker app, for example, is a dose and symptom logging tool, nothing more, not a prescription and not a checkout. Logging doses and any side effects somewhere like that means walking into a clinician visit with an actual timeline instead of a rough memory. It’s mentioned once, as one example of the habit, because the habit is the point: a tracked dose is a safer dose than a forgotten one, whatever tool gets used to track it.

What to be skeptical of

A short list of red flags, since spotting them covers most of the ground:

Be skeptical of any protocol that gives a number without naming the population it came from. The only well-evidenced figure, 2 mg daily, comes from HIV trials. A source that doesn’t mention that hasn’t actually read the studies.

Be skeptical of “cycling” schedules presented as settled science. The trials dosed daily and measured outcomes at 26 and 52 weeks [R1][R2]. The on-off cycling patterns common in off-label circles didn’t come from those trials. They’re convention passed around online, not findings.

Be skeptical of any dosing guide that never mentions glucose. The studied dose and glucose monitoring are inseparable on the label [R5]. Leaving out blood sugar means leaving out the safety half of the instruction.

And be skeptical of the assumption that more equals better. Tesamorelin raises IGF-1 as part of its mechanism, and that rise is part of why monitoring exists in the first place [R1]. Pushing the dose to chase a bigger effect isn’t something the trials support, and it moves further away from the only data that actually exists.

For competing athletes, the dose is zero

One group doesn’t need to weigh any of this: tested athletes. Tesamorelin appears explicitly on the WADA 2026 Prohibited List under category S2, as a growth-hormone-releasing hormone analogue [R6]. It’s banned in tested sport no matter the dose, the source, or whether a prescription is involved. There is no allowable dose of a prohibited substance. Anyone competing under testing should treat the answer as none, and should confirm the current list directly before going anywhere near a peptide [R6].

The bottom line

The research supports exactly one tesamorelin dose: 2 mg subcutaneously, once daily, studied in people with HIV-associated lipodystrophy, with glucose monitoring built into the protocol [R5]. That’s the entirety of what the evidence says. Everything more elaborate is extrapolation. The parts of responsible use that matter most, screening before starting and watching blood sugar afterward, were never milligram numbers to begin with. They’re the reason this drug was designed to be used with a clinician rather than pulled from a mailed vial. Write doses down. Question any protocol that hides the population or the glucose caveat. And if competing in tested sport, the number is zero.

Questions people actually ask

What is the only tesamorelin dose backed by human trials? The only trial-backed dose is 2 mg injected subcutaneously once daily. It’s the dose on the FDA-approved Egrifta label and the dose used in every registration trial, from the 2007 New England Journal of Medicine study through the 2019 Lancet HIV liver-fat trial [R5][R1][R3]. Any other number circulating, higher, lower, or cycled, didn’t come from a trial.

Is the 2 mg daily dose validated for healthy adults or for fat loss? No. Every trial behind that dose was run in people with HIV-associated lipodystrophy, the only population the FDA actually reviewed [R5]. The label states clearly that tesamorelin isn’t indicated for general weight loss. Anyone using it off-label as a healthy adult is borrowing a dose validated in a different group with a different condition, and no trial has confirmed it transfers.

Why does glucose monitoring matter for tesamorelin dosing? Because tesamorelin can raise blood sugar and impair glucose tolerance, and the studied dose was studied alongside glucose surveillance. The Egrifta label doesn’t just say “2 mg daily,” it specifies monitoring for changes in glucose metabolism [R5]. A dose taken without that monitoring is missing the safety half of the instruction, which is why this works best with a clinician involved rather than a vial arriving unsupervised.

Are tesamorelin “cycling” protocols supported by research? No. The on-off cycling schedules seen in off-label circles are convention passed around online, not findings. The actual trials dosed daily and measured results at 26 and 52 weeks [R1][R2]. Any cycling protocol presented as established deserves skepticism, since none of it was tested to the standard the daily 2 mg dose was held to.

Is more tesamorelin better if a bigger effect is the goal? No, pushing the dose isn’t a strategy the trials support. Tesamorelin works partly by raising IGF-1, and that rise is one reason monitoring exists at all [R1]. Increasing the dose to chase a larger effect moves away from the only human data available, toward risk that hasn’t been measured, not toward a better outcome.

What is the correct tesamorelin dose for someone in tested sport? Zero. Tesamorelin is named on the WADA 2026 Prohibited List under category S2 as a growth-hormone-releasing hormone analogue [R6]. It’s banned in tested sport regardless of dose, source, or prescription status. Tested athletes should treat the only allowed dose as none, and should confirm the current list directly before considering any peptide [R6].

What is tesamorelin and how does it actually work?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), and its job is to signal the pituitary gland to release more of the body’s own growth hormone. It doesn’t inject growth hormone directly. That distinction matters, since the body still governs the pulse, which is thought to reduce some of the overshoot risk seen with direct GH administration. It was developed for a defined clinical problem, not as a general-purpose performance drug.

Is tesamorelin FDA approved, and what exactly was it approved for?

Yes. Tesamorelin received FDA approval in 2010 under the brand name Egrifta, for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That remains the only approved use. Prescribing it for other purposes, general body composition or anti-aging among them, counts as off-label use, which carries a different evidence standard than the approved indication.

Does injection timing matter, and does sleep actually play a role?

The clinical trials used a once-daily subcutaneous injection, typically given in the evening before bed, loosely timed to the body’s natural overnight GH pulse. Whether that timing is strictly necessary hasn’t been tested head-to-head in published research. Most practitioners follow the evening protocol because that’s what the evidence reflects, not because sleep has been proven a required part of how the drug works.

Where can someone actually get legitimate tesamorelin, given how much gray-market product is out there?

Legitimate access in the US runs through a licensed prescriber writing a prescription that a licensed compounding pharmacy fills, since Egrifta itself is mostly distributed through specialty channels. Compounding pharmacies operating under physician oversight, FormBlends among them, work within accountability structures that research-chemical or supplement sites simply don’t have. Buying from unregulated sources leaves no reliable way to know what’s actually in the vial.

References

1. Tesamorelin (2 mg daily) reduced visceral adipose tissue by 15.2% (vs a 5.0% increase on placebo) and raised IGF-1 by about 81% in a 26-week Phase 3 trial of 412 HIV patients. New England Journal of Medicine, 2007. https://pubmed.ncbi.nlm.nih.gov/18057338/
2. Pooled analysis of two Phase 3 tesamorelin trials (806 HIV patients) at 2 mg daily; visceral-fat reduction and lipid improvements maintained to 52 weeks. Journal of Clinical Endocrinology and Metabolism, 2010. https://pubmed.ncbi.nlm.nih.gov/20554713/
3. Tesamorelin (2 mg daily) reduced liver fat in HIV patients with fatty liver disease. Lancet HIV, 2019.
4. FDA-approved Egrifta (tesamorelin) prescribing information: indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; 2 mg subcutaneous once daily; monitor for changes in glucose metabolism; long-term cardiovascular safety not established; not indicated for weight loss. U.S. Food and Drug Administration label (original 2010 approval).
5. WADA 2026 Prohibited List: growth-hormone-releasing hormone analogues, including tesamorelin, are prohibited in sport under category S2. World Anti-Doping Agency, in force January 2026.